Phase II study of S-1 with patient-reported outcome evaluation in elderly patients with previously untreated advanced non-small cell lung cancer
Hirokazu Ogino(Tokushima University), Yasuhiko Nishioka(Tokushima University), Takashi Haku(Tokushima Prefectural Central Hospital), Tomoyuki Urata(Kochi Medical School Hospital), Masaki Hanibuchi(Tokushima University), Takanori Kanematsu(Matsuyama Red Cross Hospital), Hisanori Machida(National Hospital Organization Kochi National Hospital), Soji Kakiuchi(Tokushima Prefectural Central Hospital), Yoshio Okano(Toneyama National Hospital), Nobuo Hatakeyama(National Hospital Organization Kochi National Hospital), Fumitaka Ogushi(Tokushima University), Saburo Sone(Io Therapeutics (United States)), Hisatsugu Goto(Tokushima University)
Cited by 0
Related Papers
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
|Cancer Research|2008|642
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
|Human Molecular Genetics|2004|175
The Neuromedin U-Growth Hormone Secretagogue Receptor 1b/Neurotensin Receptor 1 Oncogenic Signaling Pathway as a Therapeutic Target for Lung Cancer
|Cancer Research|2006|134
Plakophilin 3 Oncogene as Prognostic Marker and Therapeutic Target for Lung Cancer
|Cancer Research|2005|124